Clinical trials: Patients With Diabetes.
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients
This is an observational study in which data from people with type 2 diabetes mellitus (T2DM) in Germany who use the medical app "myTherapy" are studied.
- Trial name
- SMART-Finder (NCT05552339)
- Testing
- Finerenone (Kerendia, BAY94-8862), Type 2 DM drugs
- Where
- Germany
- Volunteers
- 348 people
- Sponsor
- Bayer
Diabetic Foot Ulcer
Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers
This is a phase II single-blinded study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Foot Ulcer, compared to standard therapy.
- Trial name
- NCT02619877
- Testing
- ALLO-ASC-DFU, Standard therapy
- Where
- 4 sites in South Korea
- Volunteers
- 59 people
- Sponsor
- Anterogen Co., Ltd.
Diabetes Mellitus, Type 2
A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice
The purpose of the study is to collect information on how Ryzodeg® works in real world patients and to see if Ryzodeg® can lower blood sugar levels. Participants will get Ryzodeg® as prescribed to them by their doctor.
- Trial name
- ARISE (NCT04042441)
- Testing
- Insulin Degludec/Insulin Aspart
- Where
- 64 sites in Australia, India and 4 more
- Volunteers
- 1,122 people
- Sponsor
- Novo Nordisk A/S
Diabetic Foot Ulcer
Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers
This study randomly assigns patients with diabetic foot ulcers to receive standard therapy (surgical debridement, saline-moistened gauze and offloading) alone or standard therapy plus Dermagraft(R).
- Trial name
- NCT01181453
- Testing
- Dermagraft, Comparator
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- Organogenesis
Diabetes Mellitus, Type 2
Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.
Multi-center, open, non-intervention and observational study to Evaluate the efficacy and safety of Suganon tab. or Sugamet XR tab. in patients with Type 2 diabetes
- Trial name
- NCT04326166
- Testing
- Evogliptin, Metformin and Evogliptin
- Where
- South Korea
- Volunteers
- 1,971 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes Mellitus
Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China
This is a multi-centre, cross-sectional, non-interventional study assessing blood glucose target attainment, anti-hyperglycaemic treatment pattern and the clinical characteristics in older outpatients with Type 2 Diabetes…
- Trial name
- NCT03064841
- Testing
- No Treatment
- Where
- 18 sites in China
- Volunteers
- 1,537 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes
Primary objective to evaluate the effect of a 12-week treatment period with prandial administration of Technosphere Insulin on glucose control in subjects with T2 DM.
- Trial name
- NCT00511602
- Testing
- Technosphere Insulin
- Volunteers
- 123 people
- Sponsor
- Mannkind Corporation
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
COVID-19 Pneumonia
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
- Trial name
- NCT05104437
- Testing
- Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule)
- Where
- 3 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Type 1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus
The purpose of this study is to evaluate whether an Automated Insulin Delivery (AID) System is safe to use and functions as intended with personalized basal insulin rates and when basal insulin rates are increased.
- Trial name
- NCT03849612
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 1
ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
The trial is a single-centre, randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon*) administered subcutaneously to patients with type 1…
- Trial name
- NCT02916251
- Testing
- ZP4207(dasiglucagon) glucagon analogue, Glucagon (Native glucagon)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes
GALLANT 8 Tesaglitazar Add-on to Metformin
This is a 24-week randomized double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 mg and 1 mg) given as add-on therapy to metformin in patients with type 2 diabetes, not adequately controlled…
- Trial name
- NCT00251953
- Testing
- Tesaglitazar, Metformin
- Where
- 107 sites in Australia, Canada and 9 more
- Volunteers
- 555 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the efficacy of HSK7653 (as an add-on to metformin) compared with linagliptin after 24 weeks, and the safety (up to 52 weeks) of HSK7653 in Chinese patients with Type 2 Diabetes who have…
- Trial name
- NCT04564872
- Testing
- HSK7653 10 mg Q2W, HSK7653 25 mg Q2W, Linagliptin 5 mg QD
- Where
- 2 sites in China
- Volunteers
- 465 people
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Type 2 Diabetes
A Study of OPC-262 in Patients With Type 2 Diabetes
The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in patients with type 2 diabetes by repeated administration orally for 52 weeks.
- Trial name
- NCT01046318
- Testing
- OPC-262
- Where
- 3 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetes Mellitus, Type 2
Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of long-term daily use of JARDIANCE® Tablets in Japanese patients with type 2 diabetes mellitus
- Trial name
- NCT02489942
- Testing
- Jardiance
- Where
- Japan
- Volunteers
- 8,145 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Diabetes Mellitus, Type 2
INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria
A randomized, double-blind, active control trial to determine the safety, efficacy and pharmacokinetics of INV-144 versus losartan potassium plus placebo in subjects with hypertension and Type 2 diabetes mellitus with nephropathy…
- Trial name
- NCT01398423
- Testing
- Active Control, INV-144
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- InVasc Therapeutics, Inc.
Diabetes Mellitus
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
- Trial name
- NCT00046462
- Testing
- Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Sanofi
Type 1 Diabetes
Investigation of Hyposafe H02 Device in Patients With Type 1 Diabetes
This clinical study is designed to collect data for further development of a hypoglycaemia notification algorithm. In addition, information regarding safety will be collected and analysed.
- Trial name
- NCT05495386
- Testing
- Hyposafe hypoglycaemia notification device (H02)
- Sponsor
- UNEEG Medical A/S
Diabetes Type 2
Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Randomized, double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT02496000
- Testing
- ORMD-0801
- Where
- 34 sites in United States
- Volunteers
- 188 people
- Sponsor
- Oramed, Ltd.
Type 2 Diabetes Mellitus
Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus
The study design of this trial is open-label, randomized, multi-center, parallel-group study.
- Trial name
- NCT00975065
- Testing
- vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex), metformin 1500mg plus metformin 500mg or 1000mg (Diabex)
- Where
- South Korea
- Volunteers
- 266 people
- Sponsor
- Handok Inc.